XML 63 R49.htm IDEA: XBRL DOCUMENT v3.25.2
Segment and Geographic Data (Sales And Other Financial Information By Business Segment) (Details)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Segment Reporting [Abstract]        
Number of reportable segments | segment     2  
Segment Reporting Information [Line Items]        
Net sales $ 6,022 $ 5,422 $ 11,888 $ 10,665
Reclassification to: cost of sales 2,181 2,006 4,303 3,916
Research, development and engineering expenses 407 363 812 731
Selling, general and administrative expenses 2,079 1,831 4,379 3,668
Depreciation and amortization 389 354 750 709
Amortization of intangible assets (187) (155) (354) (308)
Segment operating income 1,113 1,051 1,950 2,023
Goodwill and other impairments (55) (16) (90) (19)
Net earnings 884 825 1,538 1,613
MedSurg and Neurotechnology:        
Segment Reporting Information [Line Items]        
Net sales 3,771 3,215    
Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 6,022 5,422 11,888 10,665
Reclassification to: cost of sales 2,013 1,863 3,964 3,692
Research, development and engineering expenses 373 330 738 659
Selling, general and administrative expenses 1,727 1,531 3,511 3,045
Depreciation and amortization 162 161 317 323
Amortization of intangible assets (187) (155) (354) (308)
Segment operating income 1,747 1,537 3,358 2,946
Operating Segments | MedSurg and Neurotechnology:        
Segment Reporting Information [Line Items]        
Net sales 3,771 3,215 7,282 6,312
Reclassification to: cost of sales 1,414 1,287 2,736 2,525
Research, development and engineering expenses 246 194 471 389
Selling, general and administrative expenses 984 775 1,921 1,538
Depreciation and amortization 58 56 115 110
Segment operating income 1,069 903 2,039 1,750
Operating Segments | Orthopaedics        
Segment Reporting Information [Line Items]        
Net sales 2,251 2,207 4,606 4,353
Reclassification to: cost of sales 599 576 1,228 1,167
Research, development and engineering expenses 127 136 267 270
Selling, general and administrative expenses 743 756 1,590 1,507
Depreciation and amortization 104 105 202 213
Segment operating income 678 634 1,319 1,196
Segment Reporting, Reconciling Item, Corporate Nonsegment        
Segment Reporting Information [Line Items]        
Depreciation and amortization 40 38 79 78
Segment operating income (202) (203) (469) (466)
Segment Reconciling Items        
Segment Reporting Information [Line Items]        
Sale of inventory stepped up to fair value at acquisition (65) (9) (99) (9)
Acquisition and integration-related charges (78) (14) (263) (1)
Structural optimization and other special charges (11) (59) (52) (70)
Goodwill and other impairments (55) (16) (90) (19)
Medical device regulation (7) (15) (19) (28)
Recall-related matters (22) (17) (55) (22)
Regulatory and legal matters (7) 2 (7) 0
Net earnings $ 1,113 $ 1,051 $ 1,950 $ 2,023